CHICAGO (Reuters) – Patients with advanced multiple myeloma treated with bluebird bio’s experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small study presented on Friday.   Nick Leschly, CEO of bluebird, speaks in Houston, Texas, U.S., April 10, 2018. REUTERS/Daniel Kramer The treatment, called...Continue Reading